stoxline Quote Chart Rank Option Currency Glossary
Cara Therapeutics, Inc. (CARA)
0.6795  0.017 (2.5%)    06-12 16:00
Open: 0.651
High: 0.7198
Volume: 388,621
Pre. Close: 0.6629
Low: 0.6501
Market Cap: 37(M)
Technical analysis
2024-06-12 4:20:58 PM
Short term     
Mid term     
Targets 6-month :  0.88 1-year :  1.01
Resists First :  0.75 Second :  0.87
Pivot price 0.66
Supports First :  0.57 Second :  0.47
MAs MA(5) :  0.65 MA(20) :  0.69
MA(100) :  0.74 MA(250) :  1.41
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  41 D(3) :  33.7
RSI RSI(14): 47.8
52-week High :  4.44 Low :  0.5
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CARA ] has closed below upper band by 43.6%. Bollinger Bands are 28% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.72 - 0.73 0.73 - 0.73
Low: 0.64 - 0.65 0.65 - 0.65
Close: 0.67 - 0.68 0.68 - 0.69
Company Description

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Headline News

Wed, 12 Jun 2024
Cara Therapeutics to halt NP treatment program after trial setback By -

Wed, 12 Jun 2024
Cara Therapeutics Halts Trials for Itch Medication Difelikefalin - - TipRanks

Wed, 12 Jun 2024
Cara Therapeutics discontinues neurological condition study as drug fails - Reuters

Wed, 12 Jun 2024
Cara Therapeutics Announces Outcome Of Part A Of Kourage-1 Study Evaluating Oral Difelikefalin In Notalgia ... - XM

Wed, 12 Jun 2024
Cara to seek strategic alternatives after difelikefalin trial failure in pruritus - Seeking Alpha

Wed, 12 Jun 2024
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia ... - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 55 (M)
Held by Insiders 4.677e+007 (%)
Held by Institutions 14.4 (%)
Shares Short 2,610 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.2087e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 277 %
Return on Equity (ttm) -62.3 %
Qtrly Rev. Growth 1.694e+007 %
Gross Profit (p.s.) -82.79
Sales Per Share -186.45
EBITDA (p.s.) 0
Qtrly Earnings Growth -2.3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -88 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.97
Stock Dividends
Dividend 0
Forward Dividend 2.44e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android